Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a two-part study in subjects with hematologic malignancies designed to find the
maximum tolerated dose (MTD) of GSK690693 (Part 1). Part 2 is designed to determine the
efficacy of GSK690693 in a subset of subjects with hematologic malignancies.